Guardant Health’s CEO Helmy Eltoukhy expects the launch of the company’s new liquid biopsy test, indicated for detecting early-stage colorectal cancer, will be a “big game changer.”
The new liquid biopsy test, Guardant Reveal, is a plasma-only circulating tumor DNA (ctDNA) test indicated for detecting residual and...